You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》交銀國際對醫藥股投資評級及目標價(表)
交銀國際發表研究報告, 對醫藥股投資評級及目標價表列如下: 股份 | 投資評級 | 目標價 阿斯利康(AZN.US) | 買入 | 93.3美元 百濟神州(06160.HK) | 買入 | 208.8港元 翰森製藥(03692.HK) | 買入 | 33港元 信達生物(01801.HK) | 買入 | 84港元 中國生物製藥(01177.HK) | 買入 | 5.9港元 科倫博泰生物-B(06990.HK) | 買入 | 400港元 傳奇生物(LEGN.US) | 買入 | 65美元 藥明合聯(02268.HK) | 買入 | 51港元 和黃醫藥(00013.HK) | 買入 | 44港元 先聲藥業(02096.HK) | 買入 | 14.3港元 通化東寶(600867.SH) | 買入 | 14元人民幣 雲頂新耀(01952.HK) | 買入 | 65港元 康諾亞-B(02162.HK) | 買入 | 57港元 錦欣生殖(01951.HK) | 買入 | 3.75港元 固生堂(02273.HK) | 買入 | 42港元 恆瑞醫藥(600276.SH) | 中性 | 51元人民幣 石藥集團(01093.HK) | 中性 | 7.2港元 科倫藥業(002422.SZ) | 中性 | 40.2元人民幣 百時美施貴寶(BMY.US) | 沽售 | 33.1美元
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account